Stock on Focus: Akorn, Inc. (AKRX)

Company Profile:

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

Recent News:

During the key period of last 5 years, Akorn, Inc. sales have annually surged 52.20% on average, its earnings per share growth remained at 28.90%.

Nationwide Fund Advisors raised its position in Akorn, Inc. by 6.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).

German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn to be completed in early 2018, as the U.S. antitrust review could take longer than expected.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



AKRX’s strengths can be seen in its strong growth, robust profitability and better efficiency compared with its peers. Its net income and revenue have increased over several years. Technical indicators signal the bullish signs, as there is a bullish cross in Stochastic Oscillator and RSI (14) stands at 45.78 with positive bias. We rate Akorn, Inc. (AKRX) a STRONG BUY.

About the Author

has written 10445 stories on this site.

Copyright © 2012 Nine Stocks